Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy

被引:0
|
作者
De Lucia, Anna [1 ]
Mazzotti, Lucia [1 ,2 ]
Gaimari, Anna [1 ,2 ]
Zurlo, Matteo [1 ]
Maltoni, Roberta [3 ]
Cerchione, Claudio [4 ]
Bravaccini, Sara [5 ]
Delmonte, Angelo [6 ]
Crino, Lucio [6 ]
de Souza, Patricia Borges [1 ]
Pasini, Luigi [1 ,10 ]
Nicolini, Fabio [1 ]
Bianchi, Fabrizio [7 ]
Juan, Manel [8 ]
Calderon, Hugo [8 ]
Magnoni, Chiara [1 ,2 ]
Gazzola, Luca [1 ,2 ]
Ulivi, Paola [9 ]
Mazza, Massimiliano [1 ]
机构
[1] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Adv Cellular Therapies & Rare Tumors Unit, Meldola, Italy
[2] Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy
[3] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Healthcare Adm, Meldola, Italy
[4] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Hematol Unit, Meldola, Italy
[5] Kore Univ Enna, Dept Med & Surg, Enna, Italy
[6] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Med Oncol Dept, Meldola, Italy
[7] Fdn IRCCS Casa Sollievo Sofferenza, Unit Canc Biomarker, San Giovanni Rotondo, FG, Italy
[8] Inst Invest Biomed August Pi i Sunyer IDIBAPS, Dept Immunol, Barcelona, Spain
[9] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Translat Oncol Unit, Meldola, Italy
[10] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Meldola, FC, Italy
来源
FRONTIERS IN IMMUNOLOGY | 2025年 / 16卷
关键词
non-small cell lung cancer (NSCLC); tumor microenvironment (TME); tyrosine kinase inhibitors (TKIs); immune checkpoint inhibitors (ICIs); chimeric antigen receptor (CAR) T cell therapy; CHIMERIC ANTIGEN RECEPTOR; CAR-T-CELLS; TERTIARY LYMPHOID STRUCTURES; GROWTH-FACTOR RECEPTOR; OPEN-LABEL; EGFR-MUTATION; 1ST-LINE TREATMENT; ACQUIRED-RESISTANCE; IMMUNE CELLS; SOLID TUMORS;
D O I
10.3389/fimmu.2025.1515748
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Over the past decades, significant progress has been made in the understanding of non-small cell lung cancer (NSCLC) biology and tumor progression mechanisms, resulting in the development of novel strategies for early detection and wide-ranging care approaches. Since their introduction, over 20 years ago, targeted therapies with tyrosine kinase inhibitors (TKIs) have revolutionized the treatment landscape for NSCLC. Nowadays, targeted therapies remain the gold standard for many patients, but still they suffer from many adverse effects, including unexpected toxicity and intrinsic acquired resistance mutations, which lead to relapse. The adoption of immune checkpoint inhibitors (ICIs) in 2015, has offered exceptional survival benefits for patients without targetable alterations. Despite this notable progress, challenges remain, as not all patients respond favorably to ICIs, and resistance to therapy can develop over time. A crucial factor influencing clinical response to immunotherapy is the tumor microenvironment (TME). The TME is pivotal in orchestrating the interactions between neoplastic cells and the immune system, influencing tumor growth and treatment outcomes. In this review, we discuss how the understanding of this intricate relationship is crucial for the success of immunotherapy and survey the current state of immunotherapy intervention, with a focus on forthcoming and promising chimeric antigen receptor (CAR) T cell therapies in NSCLC. The TME sets major obstacles for CAR-T therapies, creating conditions that suppress the immune response, inducing T cell exhaustion. To enhance treatment efficacy, specific efforts associated with CAR-T cell therapy in NSCLC, should definitely focus TME-related immunosuppression and antigen escape mechanisms, by combining CAR-T cells with immune checkpoint blockades.
引用
收藏
页数:21
相关论文
共 50 条
  • [21] Targeted therapies in the treatment of non-small cell lung cancer
    De Greve, Jacques
    Decoster, Lore
    Van Meerbeek, Jan
    Vermeij, Joanna
    Teugels, Erik
    Schallier, Denis
    BULLETIN DU CANCER, 2008, 95 (03) : 358 - 364
  • [22] New targeted therapies for non-small cell lung cancer
    Lee, Eun Hye
    Kwak, Se Hyun
    Kim, Chi Young
    Gwon, Hye Ran
    Kim, Eun Young
    Chang, Yoon Soo
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2023, 66 (03): : 180 - 190
  • [23] Targeted therapies in non-small cell lung cancer in 2014
    Leduc, C.
    Besse, B.
    REVUE DES MALADIES RESPIRATOIRES, 2015, 32 (02) : 182 - 192
  • [24] Emerging targeted therapies in non-small cell lung cancer
    Khanal, Nabin
    Ganti, Apar Kishor
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (02) : 177 - 187
  • [25] Targeted therapies and immunotherapy in non-small-cell lung cancer
    Cortinovis, D.
    Abbate, M.
    Bidoli, P.
    Capici, S.
    Canova, S.
    ECANCERMEDICALSCIENCE, 2016, 10
  • [26] Immunotherapy as a targeted therapy in non-small cell lung cancer
    Rocco, Danilo
    Della Gravara, Luigi
    Avellino, Aniello
    Montesarchio, Vincenzo
    Battiloro, Ciro
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S70 - S75
  • [27] Investigating digital pathology tumor microenvironment features for immunotherapy outcome in patients with advanced non-small cell lung cancer
    Ebot, Ericka M.
    Chen, Kuei-Ting
    Biggs, Mikayla
    Lin, Douglas I.
    Elvin, Julia A.
    Frampton, Garrett M.
    Pao, James J.
    CANCER RESEARCH, 2024, 84 (06)
  • [28] Research Progress on the Microenvironment and Immunotherapy of Advanced Non-Small Cell Lung Cancer With Liver Metastases
    Fang, Yujia
    Su, Chunxia
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [29] ACTIVE IMMUNOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER
    Neninger, Elia
    Camilo Rodriguez, Pedro
    Crombet, Tania
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S194 - S194
  • [30] Circulating Tumor Cell as a Predictive Marker for Immunotherapy in Advanced Non-Small Cell Lung Cancer
    Park, C.
    Oh, H.
    Kim, M.
    Kim, B.
    Cho, H.
    Oh, I.
    Kim, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S418 - S418